Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 11/20 | 0.55 |
| ▸ | CCNC | P24863 | 2/20 | 0.51 |
| ▸ | CDK8 | P49336 | 2/20 | 0.51 |
| ▸ | CDK7 | P50613 | 6/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.43 |
| ▸ | MAT2A | P31153 | 1/20 | 0.42 |
| ▸ | FASN | P49327 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148271 | 0.84 | CHEK1 (0.59) | KDRCHEK1CCNCCDK8CDK7 | |
| SCHEMBL144764 | 0.78 | MAP2K4 (0.65) | CHEK1CDK7MAP2K4 | |
| SCHEMBL5638192 | 0.76 | HRH4 (0.56) | KDRCHEK1MAP2K4 | |
| SCHEMBL5662556 | 0.76 | CHEK1 (0.57) | CHEK1CDK7MAP2K4 | |
| SCHEMBL144396 | 0.75 | MAP2K4 (0.68) | KDRCHEK1CDK7MAP2K4 | |
| SCHEMBL5638048 | 0.75 | CHEK1 (0.60) | KDRCHEK1CDK7MAP2K4 | |
| SCHEMBL4329672 | 0.73 | HRH4 (0.65) | — | |
| SCHEMBL21225412 | 0.73 | HRH4 (0.65) | — | |
| SCHEMBL29990773 | 0.73 | HRH4 (0.65) | — | |
| Hydrochloric Acid SCHEMBL4325731 | 0.72 | HRH4 (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101884-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050070546-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070546-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CHEK1 499/4885CCNC 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.